BIIB vs. NTRA: Biogen vs. Natera Stock Comparison

Company Profile

Biogen (BIIB) and Natera (NTRA) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Natera (NTRA) has an aggressive beta of 1.58, indicating higher sensitivity to broad-market moves, while Biogen (BIIB) is defensive at 0.08 and tends to be less market-sensitive — they sit on opposite ends of the beta spectrum.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Natera (NTRA) reports a negative ROE of -10.55%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Biogen (BIIB) reports 1.87%, ranking against industry peers normally.

Natera (NTRA) reports a negative net margin of -5.66%, usually indicating a net loss over the period. Meanwhile Biogen (BIIB) reports 3.38%, ranking against industry peers normally.

Natera (NTRA) reports a negative operating margin of -7.64%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Biogen (BIIB) reports 24.12%, ranking against industry peers normally.

Profitability Metrics

Growth

Both Biogen (BIIB) at 2.22% and Natera (NTRA) at 35.90% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Only one side can be read here: Biogen (BIIB) reports EPS growth of -21.38%, ranked against its industry; Natera (NTRA) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Natera (NTRA) at 2.81 keeps current ratio within its industry’s typical mid-range, while Biogen (BIIB) at 1.95 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for BIIB.

Both Biogen (BIIB) at 0.41 and Natera (NTRA) at 0.13 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

Financial Strength Metrics

Dividends

Neither Biogen (BIIB) nor Natera (NTRA) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither Biogen (BIIB) nor Natera (NTRA) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Biogen (BIIB) trades at 107.51 times trailing earnings, ranked against its peers, while Natera (NTRA) has no P/E ratio this period.

On P/S ratio, both Biogen (BIIB) at 3.57 and Natera (NTRA) at 15.49 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

Biogen (BIIB) at 1.94 sits near its industry’s typical P/B ratio, while Natera (NTRA) at 23.99 prices above its benchmark range — NTRA looks rich relative to book.

Valuation Metrics